Trimethoprim - Allegis Pharmaceuticals

Drug Profile

Trimethoprim - Allegis Pharmaceuticals

Alternative Names: Primsol

Latest Information Update: 10 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ascent Pediatrics Inc.
  • Developer Allegis Pharmaceuticals
  • Class Antibacterials; Diaminopyrimidines
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Otitis media; Urinary tract infections

Most Recent Events

  • 03 Apr 2017 Allegis Pharmaceuticals acquires trimethoprim oral solution from Aytu Biosciences
  • 15 Mar 2016 Biomarkers information updated
  • 01 Mar 2016 Aytu and Allegis Pharmaceuticals agree to co-promote trimethoprim for acute otitis media
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top